| Literature DB >> 31143299 |
Rosa Vázquez-Fresno1, Albert Remus R Rosana1, Tanvir Sajed2, Tuviere Onookome-Okome1, Noah A Wishart1, David S Wishart1,2.
Abstract
Culinary herbs and spices have been used as both food flavoring and food preservative agents for centuries. Moreover, due to their known and presumptive health benefits, herbs and spices have also been used in medical practices since ancient times. Some of the health effects attributed to herbs and spices include antioxidant, anti-microbial, and anti-inflammatory effects as well as potential protection against cardiovascular disease, neurodegeneration, type 2 diabetes, and cancer. While interest in herbs and spices as medicinal agents remains high and their use in foods continues to grow, there have been remarkably few studies that have attempted to track the dietary intake of herbs and spices and even fewer that have tried to find potential biomarkers of food intake (BFIs). The aim of the present review is to systematically survey the global literature on herbs and spices in an effort to identify and evaluate specific intake biomarkers for a representative set of common herbs and spices in humans. A total of 25 herbs and spices were initially chosen, including anise, basil, black pepper, caraway, chili pepper, cinnamon, clove, cumin, curcumin, dill, fennel, fenugreek, ginger, lemongrass, marjoram, nutmeg, oregano, parsley, peppermint and spearmint, rosemary, saffron, sage, tarragon, and thyme. However, only 17 of these herbs and spices had published, peer-reviewed studies describing potential biomarkers of intake. In many studies, the herb or spice of interest was administrated in the form of a capsule or extract and very few studies were performed with actual foods. A systematic assessment of the candidate biomarkers was also performed. Given the limitations in the experimental designs for many of the published studies, further work is needed to better evaluate the identified set of BFIs. Although the daily intake of herbs and spices is very low compared to most other foods, this important set of food seasoning agents should not be underestimated, especially given their potential benefits to human health.Entities:
Keywords: Diet; Food exposure biomarker; Herbs; Metabolomics; Spices
Year: 2019 PMID: 31143299 PMCID: PMC6532192 DOI: 10.1186/s12263-019-0636-8
Source DB: PubMed Journal: Genes Nutr ISSN: 1555-8932 Impact factor: 5.523
Scientific and common names of selected spices evaluated in this review
| Num. | Name of spice | Scientific name | Part of the plant |
|---|---|---|---|
| 1 | Anise |
| Seed/fruit |
| 2 | Basil |
| Leaf |
| 3 | Black pepper |
| Berry |
| 4 | Caraway |
| Fruit |
| 5 | Chili pepper |
| Fruit |
| 6 | Cinnamon |
| Bark |
| 7 | Clove |
| Bud |
| 8 | Cumin |
| Seed |
| 9 | Dill |
| Leaf/seed |
| 10 | Fennel |
| Leaf/seed |
| 11 | Fenugreek |
| Seed |
| 12 | Ginger |
| Root |
| 13 | Lemongrass |
| Leaf |
| 14 | Marjoram |
| Leaf |
| 15 | Nutmeg |
| Seed |
| 16 | Oregano |
| Leaf |
| 17 | Parsley |
| Leaf |
| 18 | Peppermint |
| Leaf |
| 19 | Rosemary |
| Leaf |
| 20 | Saffron |
| Stigma (flower) |
| 21 | Sage |
| Leaf |
| 22 | Spearmint |
| Leaf |
| 23 | Tarragon |
| Leaf |
| 24 | Thyme |
| Leaf |
| 25 | Turmeric (curcumin) |
| Root |
List of studies reporting candidate biomarkers for herb and spice intake
| Dietary factor | Study design | Subjects | Analytical method | Sample type | Discriminating metabolites/candidate biomarkers | Primary Ref. |
|---|---|---|---|---|---|---|
| Anise (anethole admn.) | Acute human study. [methoxy-14C]-labeled compound | 5 (males) | Radiochemical (14C labeled) and HPLC | Urine (2 h–10 h, 24 h, and 48 h) | 4-methoxybenzoic acid, 4-methoxyhippuric acid, 3 unknown compounds | [ |
| Anise-based alcoholic drink | Dose escalating study (120 ml, 200 ml, 360 ml “Helenas Ouzo” (anethole-containing drink) | 1 | HS-SPME-GC–MS | Serum (1, 2, 4, 8, and 24 h) | Anethole | [ |
| Observational study: drivers under the influence of alcoholic-containing anethole drink | 50 | Serum | ||||
| Acute crossover study (5 g of capsicum extract) | 12 (males) | HPLC | Plasma | Capsaicin | [ | |
| Double-blind, randomized, placebo-controlled, dose-escalating (15 or 30 mg capsinoids extract) | 24 (males) | LC-MS/MS and HPLC-UV | Plasma (15 min, 30 min, 1 h, 2 h, 4 h, 8 h, and 24 h) | Capsiate, dihydrocapsiate, nordihydrocapsiate, vanillyl alcohol | [ | |
| Case study. 200 ml paprika carotenoid beverage | 5 (young, healthy) | HPLC-UV-VIS and Q-TOF-MS/MS | Plasma (0 week, 2 weeks, 4 weeks), erythrocytes | β-cryptoxanthin, cucurbitaxanthin A, cryptocapsin, lutein, zeaxanthin, capsanthin, capsanthone | [ | |
| Cinnamon | Four-way crossover study | 24 | HPLC MS/MS | Plasma and urine | 7-hydroxycoumarin | [ |
| Fennel (fennel tea) | Single-dose acute study (500 ml of fennel tea) | 7 | LC-MS/MS and GC-GC-MS | Urine (1.5, 4, 8, 14, 24 h) | Estragole, 1′-hydroxyestragole, | [ |
| Dose-escalation study (250, 500, 1000 ml fennel tea). | 1 | Plasma (0.75,1.5, 2, 2.5 h) | ||||
| Fennel, basil, and tarragon | 15 mL fennel extract; 15 ml tarragon extract; 15 ml basil brewed | NP | IS-R-DLLME and HPLC | Plasma (2 h, 4 h, and 8 h) and Urine (3 h, 6 h, and 9 h) | [ | |
| Ginger (extract) | Acute single dose: 2 g ginger extracts | 9 (healthy) | LC-MS/MS | Plasma (0.25 h, 0.5 h, 0.75 h, 1 h, 2 h, 4 h, 6 h, 10 h, 24 h, 48 h, and 72 h) | 10-Gingerol, 6-Shogaol, 6-Gingerol-G, 8-Gingerol-G 10-Gingerol-G, 6-Shogaol-G 6-Gingerol-S, 8-Gingerol-S, 10-Gingerol-S, 6-Shogaol-S | [ |
| Multiple dose: 24-day randomized controlled trial. 250 mg ginger extract | 30 (healthy) | Plasma (0–24 h) and colon (biopsy) | 6-Gingerol-G (plasma), 10-Gingerol-G (plasma), 6-Gingerol-S (plasma), 10-Gingerol-G (colon), 10-Gingerol-S (colon) | |||
| Multiple dose: 24-day randomized controlled trial. 250 mg ginger extract | 20 (high-risk colorectal cancer) | Plasma (0-24 h) and colon (biopsy) | 6-Gingerol-G (plasma), 10-Gingerol-G (plasma), 6-Gingerol-S (plasma) 10-Gingerol-G (colon), 10-Gingerol-S (colon) | |||
| Ginger | Dose escalation study: 100 mg, 250 mg, 500 mg, 1 g, 1.5 g, 2 g ginger extract (capsule) | 27 (healthy) | HPLC-ECD, HPLC-UV | Plasma (15 min, 30 min, and 45 min, 1 h, 2 h, 4 h, 6 h, 10 h, 24 h, 48 h, and 72 h) | 6-Gingerol-G, 8-Gingerol-G, 10-Gingerol-G, 6-Shogaol-G, 6-Gingerol-S, 10-Gingerol-S | [ |
| Ginger (ginger tea) | Acute study. 2× (18 g/bag) ginger tea | 3 (healthy males) | LC/ESI-MS/MS | Urine (0–2 h, 2–4 h, 4–6 h, 6–9 h, 9–12 h, and 12–24 h) | 5-Cys-6S, 5-NAC-6S, 5-Cys-Gly-6S, 5-Cys-M6, 5-NAC-M6, 5-Cys-Gly-M6, 5-Cys-8S, 5-Cys-M6’, 5-Cys-10S, 5-Cys-M6" | [ |
| Marjoram (extract) | Acute single oral dose (3.75 g) of | 6 (healthy) | HPLC-CEAD | Urine (24 h, 48 h) | Protocatechuic acid, | [ |
| Nutmeg | Acute oral dose in rats (100 mg/kg body mass) of EL, MY, and SA or a single 500 mg/kg body mass of nutmegs | 2 rats × each substance and dose | GC-MS | Urine (24 h) | O-demethyl elemicin*, O-demethyl dihydroxy elemicin*, demethylenyl myristicin*, dihydroxy myristicin*, demethylenyl safrole* | [ |
| Observational exploratory toxicological study: after nutmeg abuse (~ 5 nutmegs) | 1 | |||||
| Oregano (extract) | Oregano extract (25, 75, or 225 mg/kg | 15 mice | HPLC–MS/MS | Plasma and brain tissue | Carvacrol | [ |
| Parsley | Randomized crossover with two 1-week intervention periods in succession, supplemented with parsley 20 g parsley/MJ | 14 (healthy) | HPLC-DAD | Urine (24 h) | Apigenin | [ |
| Parsley | Acute human study. (149.45 ± 35.21 g parsley) | 11 (healthy) | HPLC-ECD | Plasma (4–11 h, 28 h), urine (24 h), and red blood cells | Apigenin | [ |
| Peppermint oil (capsule) | Acute pharmacokinetic study. Intake of 0.4 ml peppermint oil in either colpermin or gelatine capsules (91–97 mg capsule) | 6 (healthy) | NP | Urine (24 h) | Menthol-G | [ |
| 6 (ileostomy) | ||||||
| Peppermint oil | Acute randomized intake of 0.6 ml peppermint oil in either | 13 (healthy) | GC-MS | Urine (2 h-interval for 14 h + single overnight (10 h) | Menthol-G | [ |
| Peppermint oil (capsule) | 180 mg peppermint oil enteric-coated capsule (peroral administration) | 4 (males) | GC-FID | Urine (2-h interval up to 14 h) | Menthol-G | [ |
| Peppermint oil (capsule) | Acute (400 mg peppermint oil in enteric-coated capsule) and repeated 4 weeks later | 5 (healthy) | 2H-NMR | Urine (2 h, 4 h, 6 h, and 8 h) | Menthol-G | [ |
| Peppermint oil (capsule) | (1) 400 mg of enteric-coated peppermint oil capsules and 6 g of 99% [U-13C] glucose | 1 (female) | 13C-NMR | Urine (2-4 h) | 13C-menthol-G | [ |
| (2) Primed infusion of [U-13C] glucose + 400 mg enteric-coated peppermint oil capsules | 4 (severe heart failure) | Urine (2 h) | ||||
| Peppermint oil (L-menthol preparation) | Escalating-single-dose, randomized, double-blind, placebo-controlled (menthol preparation, 80–320 mg). Intragastric spraying of peppermint oil | 24 (males) | GC-MS | Plasma (5, 10, 30, 60, 120, and 240 min and 8, 12, and 24 h after each dose) | Menthol, menthol-G, M7, M9, M11, M29 | [ |
| Urine (before dosing (−12–0 h) and 0–4 h, 4–8 h, 8–12 h, and 12–24 h after | Menthol-G, M2, M3–11, M12, M13–18, M19–21, M22–28, M29, M30–32. | |||||
| Rosemary (extract) | Acute, controlled, randomized study. Rosemary extract enriched in carnosic acid 40% ( | 24 Zucker rats | HPLC/QTOF-MS and HPLC-UV | Gut, liver, plasma, brain, | Carnosic acid-G, carnosol-G, rosmanol-G, carnosic acid 12 methyl ether, 5,6,7,10-tetrahydro-7-hydroxyrosmariquinone, carnosic glutathione oxidized, carnosol-S, rosmanol-S, rosmarinic acid, carnosic cysteine, carnosic glutathione, rosmadial-G, rosmanol, ipirosmanol, epiisorosmanol, rosmadial/rosmanol quinone, rosmanol/epirosmanol methyl ether, carnosol, rosmadial methyl ether, epirosmanol ethyl ether, epiisorosmanol methyl ether, carnosol methyl ether, carnosic acid. | [ |
| Subchronic, controlled, randomized study Rosemary extract enriched in carnosic acid 40% ( | ||||||
| Saffron (tea) | Single-dose acute study. 200 mg saffron in 150 ml water (saffron tea) | 4 (healthy) | SPE-HPLC-DAD | Plasma (0 h, 2 h, and 24 h) | [ | |
| Saffron (purified crocetin) | Open-label, single dose escalation of crocetin (7.5, 15 and 22.5 mg) | 10 (healthy) | HPLC | Plasma (1 , 2 h, 4 h, 6 h, 8 h, 10 h, and 24 h) | Crocetin | [ |
| Sage (tea) | Acute human study (1.02 mg 1,8-cineole) in sage tea | 1 (female) | SPME-GC-MS and LC-MS/MS | Plasma (0.75 h, 1.7 h, 3.25 h, 6.75 h, and 24 h) and urine (2 h, 5 h, 7 h, 10 h, 17 h, 21 h, 28 h, 32 h, 35 h, 44 h, 50 h, 53 h, 60 h, and 69 h) | 1,8-cineole, 2-hydroxy-1,8-cineole, 3-hydroxy-1,8-cineole, 7-hydroxy-1,8-cineole, 9-hydroxy-1,8-cineole. | [ |
| Thyme (tablet) | Acute study. A single dose of a Bronchipret® TP (tablet equivalent to 1.08 mg thymol) | 12 | HS-SPME-GC-MS and LC-MS/MS | Plasma (0.25 h, 0.5 h, 0.75 h, 1 h, 1.5 h, 2 h, 2.5 h, 3 h, 3.5 h, 4 h, 5 h, 6 h, 7 h, 8 h, 9 h, 10 h, 11 h, 12 h, 14 h, 24 h, 31 h, 38 h, 48 h, 55 h, 62 h, and 72 h) | Thymol-S | [ |
| Urine (0 to 3 h, 3 to 6 h, 6 to 9 h, 9 to 14 h, 14 to 24 h, 24 to 31 h, 38 to 48 h, 48 to 55 , 55 to 62 h, and 62 to 72 h) | Thymol-G, thymol-S | |||||
| Thyme | Acute intake of 1.5 g of thyme extract | 12 Wistar rats | μSPE-UPLC-MS/MS | Plasma | Thymol-S, thymol-G, luteolin-S, luteolin-G, hydroxyphenylpropionic acid-S, coumaric acid-S, caffeic acid-S, ferulic acid-S, ferulic acid-G, hydroxybenzoic acid, and dihydrophenylpropionic acid-S | [ |
| Thyme (olive oil enriched with thyme polyphenols) | Randomized, double-blind, controlled, cross-over trial. Administration of 25 ml/day (VOO)/VOO + PC/VOO + PC + PC of thyme | 33 (hypercholesterolemic) | μSPE-UPLC-ESI-MS/MS | Plasma | Thymol-S, hydroxyphenylpropionic acid-S, caffeic acid-S | [ |
| Urine (24 h) | Thymol-S, Thymol-G, hydroxyphenylpropionic acid-S, | |||||
| Thyme (olive oil enriched with thyme) | (1) In vitro colonic fermentation (0 to 48 h) | 3 (healthy) | UPLC-ESI-MS/MS and GC-FID | Feces (in vitro fermentation) | Thymol, carvacrol, 2-(3′,4′-dihydroxyphenyl) acetic acid, 2-(4′-hydroxyphenyl) acetic acid, phenylacetic acid, 3-(4′-hydroxyphenyl) propionic acid, phenylpropionic acid. | [ |
| 2-(3′,4′-dihydroxyphenyl) acetic acid, 2-(4′-hydroxyphenyl) acetic acid, Phenylacetic acid, 3-(4′-hydroxyphenyl) propionic acid, phenylpropionic acid | ||||||
| Caffeic acid, | ||||||
| 3-(3′, 4′-dihydroxyphenyl) propionic acid; hydroxyphenylpropionic acid; phenylpropionic acid, 2-(3′,4′-dihydroxyphenyl) acetic acid, 2-(4′-hydroxyphenyl) acetic acid; phenylacetic acid | ||||||
| (2) Human intervention study: 25 ml/day of a thyme phenol-enriched olive oil for 3 weeks | 10 | Feces (in vivo | Carvacrol, 2-(4-hydroxyphenyl) acetic acid, 3-(3′-4′-dihydroxyphenyl) propionic acid, hydroxyphenylpropionic acid, phenylpropionic acid | |||
| Turmeric (curcuminoids in capsule) | Randomized double blind placebo (1 g/day, 4 g/day, placebo), 6 months | 31 (elderly) | LC-MS/MS | Plasma (2–2.5 h after 1 month) | Curcumin, DMC BDMC, THC, ferulic acid, vanillic acid | [ |
| Turmeric (curcuminoids in capsule) | Acute study | 2 (healthy) | LC-MS/MS | Plasma | COG | [ |
| Turmeric (curcuminoidsin nanoemulsion) | Acute study (2 g nanoemulsion curcuminoids) | 2 (healthy) | LC-MS/MS | Plasma | Curcumin, COG, COS, DMC, BDMC, and THC | [ |
| Turmeric (curcuminoids in capsule) | Nonrandomized, open-label, phase II trial (starting dose 8 g curcuminoids) 8 weeks | 25 (pancreatic cancer) | LC-MS | Plasma (1 h, 2 h, 6 h, 24 h, 48 h, 72 h, day 8 and after 4 weeks | COG and COS | [ |
| Turmeric (curcuminoids in capsule) | Dose escalation. 450–3600 mg/day 1 week | 12 (hepatic metastasis from colorectal cancer) | HPLC-UV, LC-MS | Plasma and liver tissue | Hexahydrocurcumin (liver), hexahydrocurcuminol (liver), curcumin (plasma), COG (plasma), COS (plasma). | [ |
| Turmeric (curcuminoids in capsule) | Acute study. | 12 (colorectal carcinoma) | HPLC-UV HPLC-MS | Plasma and colorectal tissue | Curcumin (plasma and colorectal tissue), COG and COS (colorectal tissue) | [ |
| Turmeric (curcuminoids-different administration types) | Randomized double blind crossover study with formulated (CP, CTR, CHC) and unformulated (CS) curcumin | 12 (healthy) | LC-MS/MS | Plasma (1 h, 2 h, 3 h, 4 h, 5 h, 6 h, 8 h, and 12 h) | Curcumin, DMC, BDMC, THC | [ |
| Turmeric (curcuminoids in capsule) | 14-day intervention (2.35 g capsule) | 24 (colorectal cancer) | UPLC-UV, LC-MS/MS | Plasma, urine and colon tissue | Curcumin, BDMC, DMC, BDMC-S, DMC-S, COS, COG, BDMC-G, DMC-G | [ |
| Turmeric (Theracurmin®) | Acute dose escalation 150 mg and 210 mg | 6 (healthy) | LC-MS/MS | Plasma (0 h, 1 h, 2 , 4 h, 6 , 24 h) | Curcumin | [ |
| Turmeric (Theracurmin®) | Multi-week dose escalation | 16 (pancreatic or biliary tract cancer) | LC-MS/MS | Plasma (2 h) | Curcumin | [ |
| Turmeric (turmeric fresh derived curcuminoids vs. std. curcumin) | Multi-week double crossover study. 250 mg/kg body weight | 18 (mice) | LC-DAD-ESI-MS/MS | Plasma (0 h, 0.5 , 1 h, 3 h, 5 h, 8 h, 12 h) | Curcumin, DMC, BMDC | [ |
| Acute, single-blind crossover study, 100 mg, 250 mg, 1000 mg | 15 (healthy) | |||||
| Turmeric (C3 complex) | Acute study. 1 single dose (4 g) | 8 (healthy) | HPLC | Serum | Curcumin | [ |
| 3–4-week intervention study. (8 g/day) | 15 (with HNSCC) | |||||
| Turmeric (curcuma extract capsule) | Dose escalation: 440 mg–2200 mg/day. 4 months | 15 (colorectal cancer) | HPLC-UV | Blood, urine, feces | COS (only detected in feces) | [ |
| Turmeric (C3 complex) | Dose escalation study. 4-month intervention (450, 900, 1800, 3600 mg). 4 months | 15 (colorectal adenocarcinoma patients) | LC-MS | Plasma, urine, feces | Curcumin (plasma, urine, feces), COG (plasma, urine), DMC (plasma, urine), BDMC (plasma), DMC-G (plasma, urine), DMC-S (plasma) COS (plasma, urine, and feces). | [ |
| Turmeric (C3 complex, 10 or 12 g) | Acute study | 12 (healthy) | HPLC | Plasma | COG and COS | [ |
| Turmeric | 3-month intervention with different doses each group (500, 1000, 2000, 4000, 8000 mg/day) | 25 cancer | HPLC-UV | Serum (0 h, 0.5 h, 1 h, 1.5 h, 2 h, 2.5 h, 3 h, 4 h, 6 h, 8 h, 12 h, 14 h, and 24 h) | Curcumin (only in serum) | [ |
| Urine (0–2 h, 2–4 h, 4–8 h, and 8–24 h) | ||||||
| Turmeric (Theracurmin®) | Acute study. Curcumin in powder and Theracurmin® in liquid (30 mg). | 12 Sprague-Dawley rats and 14 humans | LC-MS/MS | Plasma | Theracurmin and curcumin | [ |
| Turmeric (curcumin) | Dose escalation study. C3 complex adm. 500 mg, 1000 mg, 2000 mg, 4000 mg, 6000 mg, 8000 mg, 10,000 mg, and 12,000 mg) | 24 | HPLC | Plasma and serum | Curcumin (just in serum at 10000 and 12,000 mg) | [ |
Adm, administration; BDMC, bisdemethoxycurcumin, CEAD, coulometric electrode array detector; CHC, combination of hydrophilic carrier, cellulosic derivatives, and natural antioxidants; C-NMR, carbon nuclear magnetic resonance; COG, curcumin-O-glucoronide. COS, curcumin-O-sulfate; CP, curcumin phytosome formulation; CS, standardized curcumin mixture; CTR formulation with volatile oils of turmeric rhizome, Cys, cysteinyl; DAD, diode array detector; DMC, demethoxycurcumin, ECD, electrochemical detection. EL, elemicin; ESI, electrospray ionization; FID, flame ionization detector; −G, glucuronide; Gly, glycinyl; H-NMR, proton nuclear magnetic resonance; HPLC, high-performance liquid chromatography; HNSCC head and neck squamous cell carcinomas; HS-SPME, headspace solid-phase microextraction; IS-R-DLLME, in-syringe reversed dispersive liquid-liquid microextraction; LC, liquid chromatography; months, months; MJ, megajoules; MY, myristicin, M6, 1-(4′-hydroxy-3′-methoxyphenyl)-4-decen-3-ol; M6′, 1-(4′-hydroxy-3′-methoxyphenyl)-4-dodecen-3-ol; M6′′, 1-(4′-hydroxy-3′-methoxyphenyl)-4-tetradecen-3-ol; M29, menthol sulfoconjugate; M7, 9, 11, hydroxyl menthol glucuronide. M3–11, hydroxyl menthol glucuronide; M19–21, dihydroxyl menthol glucuronide. M2, aldehyde-menthol glucuronide; M13–18, carboxylate-menthol or aldehyde-hydroxyl menthol glucuronide; M29–32, sulfate conjugates; M12, dialdehydementhol glucuronide (M12); MS mass spectrometry; NAC, N-acetylcysteinyl; NP, not provided; PC, phenolic compounds; Q-TOF, quadrupole time-of-flight; S, sulfate; SA, safrole; THC, tetrahydrocurcumin; UPLC, ultra-high performance liquid chromatography; UV ultraviolet; VIS, visible; VOO, virgin olive oil. weeks, week; w/w, weight per weight; μSPE, microelution solid-phase extraction; 6S, 6-shogaol; 8S, 8-shogaol; 10S, 10-shogaol
*In the study performed in rats, there were other metabolites also identified but not found in the human sample analyzed so they were not considered in this table
Summary of the selected candidate BFIs of herbs and spices and their assessment relative to the nine validation criteria/questions described in [33]
| Food item | Metabolites | Biofluid locations | Questions* | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Anise | Anethole | Serum | N | Y | Y | U | U | Y | U | Y | N |
| 4-methoxyhippuric acid1 | Urine | N | Y | Y | U | U | U | Y | N | N | |
| 4-methoxybenzoic acid1 | Urine | N | Y | Y | U | U | U | Y | N | N | |
| Basil | Estragole | Plasma | N | Y | Y | U | U | N | U | Y | N |
| Estragole | Urine | N | Y | Y | U | U | N | U | Y | N | |
| Plasma | N | Y | Y | U | U | Y | U | Y | N | ||
| Urine | N | Y | Y | U | U | Y | U | Y | N | ||
|
| Plasma | N | Y | Y | U | U | N | U | Y | N | |
|
| Urine | N | Y | Y | U | U | N | U | Y | N | |
| Capsaicin | Plasma | Y | Y | Y | U | U | U | U | U | N | |
| Capsiate | Plasma | Y | U | N | U | U | U | U | N | N | |
| Dihydrocapsiate | Y | U | N | U | U | U | U | N | N | ||
| Nordihydrocapsiate | Y | U | N | U | U | U | U | N | N | ||
| Vanillyl alcohol | N | U | N | U | U | U | U | N | N | ||
| β-Cryptoxanthin | Plasma and erythrocy-tes | N | Y | N | Y | U | N | U | N | N | |
| Cucurbitaxanthin A | Y | Y | N | Y | U | U | U | N | N | ||
| Lutein | N | Y | N | Y | U | N | U | N | N | ||
| Zeaxanthin | N | Y | N | Y | U | N | U | N | N | ||
| Capsanthin | Y | Y | N | Y | U | U | U | N | N | ||
| Capsanthone | Y | Y | N | Y | U | U | U | N | N | ||
| Cryptocapsin | Y | Y | N | Y | U | U | U | N | N | ||
| Cinnamon | 7-hydroxycoumarin | Plasma | Y | Y | Y | U | Y | U | Y | Y | N |
| 7-hydroxycoumarin | Urine | Y | Y | Y | U | Y | U | Y | Y | N | |
| Fennel | Plasma | N | Y | Y | U | U | Y | U | Y | N | |
| Urine | N | Y | Y | U | U | Y | U | Y | N | ||
| 1′-hydroxyestragole-G | Plasma | N | Y | N | U | U | U | U | Y | N | |
| 1′-hydroxyestragole | Urine | N | Y | N | U | U | U | Y | Y | N | |
| 1′-hydroxyestragole-G | Urine | N | N | N | U | U | U | U | Y | N | |
| Plasma | N | N | N | U | U | U | U | Y | N | ||
| Urine | N | N | N | U | U | U | U | Y | N | ||
| Estragole | Plasma | N | Y | Y | U | U | N | U | Y | N | |
| Estragole | Urine | N | Y | Y | U | U | N | U | Y | N | |
| Plasma | N | Y | Y | U | U | Y | U | Y | N | ||
| Urine | N | Y | Y | U | U | Y | U | Y | N | ||
| Ginger | 10-Gingerol | Plasma | Y | Y | Y | N | U | U | Y | Y | N |
| 6-Shogaol | Y | Y | Y | N | U | U | Y | Y | N | ||
| 6-Gingerol -G | Y | Y | Y | N | U | U | Y | Y | N | ||
| 8-Gingerol-G | Y | Y | Y | N | U | U | Y | Y | N | ||
| 10-Gingerol-G | Y | Y | Y | N | U | U | Y | Y | N | ||
| 6-Shogaol-G | Y | Y | Y | N | U | U | Y | Y | N | ||
| 6-Gingerol-S | Y | Y | Y | N | U | U | Y | Y | N | ||
| 8-Gingerol-S | Y | Y | Y | N | U | U | Y | Y | N | ||
| 10-Gingerol-S | Y | Y | Y | N | U | U | Y | Y | N | ||
| 6-Shogaol-S | Y | Y | Y | N | U | U | Y | Y | N | ||
| Marjoram ( | Urine | N | Y | Y | U | U | U | Y | Y | N | |
| Vanillic acid | N | Y | Y | U | U | U | Y | Y | N | ||
| N | Y | Y | U | U | U | Y | Y | N | |||
| Ferulic acid | N | Y | Y | U | U | U | Y | Y | N | ||
| 3,4-dihydroxyphenylacetic acid | N | Y | Y | U | U | U | Y | Y | N | ||
| Protocatechuic acid | N | Y | Y | U | U | U | Y | Y | N | ||
| Syringic acid | N | Y | Y | U | U | U | Y | Y | N | ||
| Caffeic acid | N | Y | Y | U | U | U | Y | Y | N | ||
| N | Y | Y | U | U | U | Y | Y | N | |||
| Nutmeg | O-demethyl elemicin | Urine | Y | Y | N | U | U | Y | U | N | N |
| O-demethyl dihydroxy elemicin | Y | Y | N | U | U | Y | U | N | N | ||
| Demethylenyl myristicin | Y | Y | N | U | U | Y | U | N | N | ||
| Dihydroxy myristicin | Y | Y | N | U | U | Y | U | N | N | ||
| Demethylenyl safrole | Y | Y | N | U | U | Y | U | N | N | ||
| Parsley | Apigenin | Plasma | N | Y | Y | U | U | U | Y | U | N |
| Apigenin | Red cells | N | N | Y | U | U | U | Y | U | N | |
| Apigenin | Urine | N | Y | Y | U | U | U | Y | Y | N | |
| Peppermint (capsule, oral admin.) | Menthol glucuronide | Urine | Y | Y | Y | U | U | U | Y | Y | N |
| Peppermint (intragastric spray) | Menthol | Plasma | Y | Y | Y | U | U | U | U | Y | N |
| Menthol glucuronide | Plasma | Y | Y | Y | U | U | U | Y | Y | N | |
| M7 | Plasma | U | Y | Y | U | U | U | Y | Y | N | |
| M9 | Plasma | U | Y | Y | U | U | U | Y | Y | N | |
| M11 | Plasma | U | Y | Y | U | U | U | Y | Y | N | |
| M29 | Plasma | U | Y | Y | U | U | U | Y | Y | N | |
| M2–16, M18–21, M24, M29–31 | Urine | U | U | Y | U | U | U | Y | Y | N | |
| Saffron | Crocetin | Plasma | Y | Y | Y | U | U | U | Y | Y | N |
| Sage | 1,8 cineole | Plasma | N | Y | U | U | U | U | N | Y | N |
| 1,8 cineole | Urine | N | Y | N | U | U | U | N | Y | N | |
| 2-OH-1,8-cineole | Plasma | N | Y | N | U | U | U | N | Y | N | |
| 2-OH-1,8-cineole | Urine | N | Y | N | U | U | U | N | Y | N | |
| 3-OH-1,8-cineole | Plasma | N | N | N | U | U | U | N | Y | N | |
| 3-OH-1,8-cineole | Urine | N | Y | N | U | U | U | N | Y | N | |
| 7-OH-1,8-cineole | Plasma | N | N | N | U | U | U | N | Y | N | |
| 7-OH-1,8-cineole | Urine | N | Y | N | U | U | U | N | Y | N | |
| 9-OH-1,8-cineole | Plasma | N | Y | N | U | U | U | N | Y | N | |
| 9-OH-1,8-cineole | Urine | N | Y | N | U | U | U | N | Y | N | |
| Tarragon | Estragole | Plasma | N | Y | Y | U | U | N | U | Y | N |
| Estragole | Urine | N | Y | Y | U | U | N | U | Y | N | |
| Plasma | N | Y | Y | U | U | Y | U | Y | N | ||
| Urine | N | Y | Y | U | U | Y | U | Y | N | ||
|
| Plasma | N | Y | Y | U | U | Y | U | Y | N | |
|
| Urine | N | Y | Y | U | U | Y | U | Y | N | |
| Thyme | Thymol-S | Plasma | N | Y | Y | U | U | Y | Y | Y | N |
| Thymol-S | Urine | N | Y | Y | U | U | Y | Y | Y | N | |
| Thymol-G | Urine | N | Y | Y | U | U | Y | Y | Y | N | |
| Caffeic acid-S | Urine | N | Y | N | U | U | Y | Y | Y | N | |
| OH-phenylpropionic acid-S | Plasma | N | Y | N | U | U | Y | Y | Y | N | |
| OH-phenylpropionic acid-S | Urine | N | Y | N | U | U | Y | Y | Y | N | |
| Plasma | Y | Y | N | U | U | Y | Y | Y | N | ||
| Urine | Y | Y | N | U | U | Y | Y | Y | N | ||
| Carvacrol | Feces | N | N | N | U | U | U | Y | U | N | |
| 2-(4-hydroxyphenyl)acetic acid | Feces | U | N | N | U | U | U | Y | U | N | |
| 3-(3′-4′-dihydroxyphenyl)propionic acid | Feces | U | N | N | U | U | U | Y | U | N | |
| OH-phenylpropionic acid | Feces | Y | N | N | U | U | U | Y | U | N | |
| 3-phenylpropionic acid | Feces | U | N | N | U | U | U | Y | U | N | |
| Turmeric (curcuminoids in capsule, or nanoemulsion) | Curcumin | Plasma | Y | Y | Y | U | Y | U | Y | Y | Y |
| Curcumin | Serum | Y | Y | Y | U | U | U | Y | N | N | |
| Curcumin | Urine | Y | Y | U | U | U | U | Y | U | N | |
| Curcumin | Feces | Y | Y | U | U | U | U | Y | U | N | |
| Curcumin | Colon | Y | Y | Y | Y | Y | Y | Y | U | N | |
| DMC | Plasma | Y | Y | Y | U | Y | U | Y | Y | Y | |
| DMC | Urine | Y | Y | U | U | U | U | Y | U | N | |
| DMC | Colon | Y | Y | U | Y | U | U | U | U | N | |
| DMC-G | Plasma | Y | Y | U | Y | U | U | U | U | N | |
| DMC-G | Urine | Y | Y | U | Y | U | U | U | U | N | |
| DMC-S | Plasma | Y | Y | U | Y | U | U | U | U | N | |
| BDMC | Plasma | Y | Y | Y | U | Y | U | Y | Y | Y | |
| BDMC | Urine | Y | Y | U | U | U | U | Y | U | N | |
| BDMC | Colon | Y | Y | U | Y | U | U | U | U | N | |
| THC | Plasma | Y | Y | Y | U | Y | U | Y | Y | Y | |
| COG | Plasma | Y | Y | Y | U | U | U | Y | Y | Y | |
| COG | Urine | Y | Y | U | U | U | U | Y | U | N | |
| COG | Colon | Y | Y | U | Y | U | U | U | U | N | |
| COS | Plasma | Y | Y | Y | U | Y | U | Y | Y | Y | |
| COS | Urine | Y | Y | U | U | U | U | Y | U | N | |
| COS | Colon | Y | Y | U | Y | U | U | U | U | N | |
| COS | Feces | Y | Y | U | U | U | U | Y | U | N | |
| Hexahydrocurcumin | Liver | Y | Y | N | U | U | U | Y | U | N | |
| Hexahydrocurcuminol | Liver | Y | Y | N | U | U | U | Y | U | N | |
| Ferulic acid | Plasma | N | N | N | U | Y | U | N | N | N | |
| Vanillic acid | Plasma | N | N | N | U | Y | U | N | N | N | |
| Turmeric (Theracurmin1) | Curcumin | Plasma | Y | Y | Y | U | U | U | U | U | N |
| Turmeric-fresh curcuminoids (capsule) | Curcumin | Plasma | Y | Y | Y | U | U | U | Y | U | N |
| DMC | Plasma | Y | Y | N | U | U | U | U | U | N | |
| BDMC | Plasma | Y | Y | N | U | U | U | U | U | N | |
−G, glucuronide; −S, sulfate; BMDC, bisdemethoxycurcumin; DMC, demethoxycurcumin; DMC-G, demethoxycurcumin glucuronide; THC tetrahydrocurcumin; COG curcumin-O-glucoronide. COS, curcumin-O-sulfate. M29, menthol sulfoconjugate; hydroxyl menthol; M7, 9, 11 glucuronide; M3–11, hydroxyl menthol glucuronide; M19–21, dihydroxyl menthol glucuronide; M2, aldehyde-menthol glucuronide; M13–18 carboxylate-menthol, or aldehyde-hydroxyl menthol glucuronide; M29–32, sulfate conjugates; M12, dialdehydementhol glucuronide
Theracurmin, commercialized nanoparticle curcumin to increase its absorption
*Possible answers are Y (yes), N (no), or U (unknown or uncertain, or not specified in the study)
Biological/nutritional validation and applicability:
1. Is the marker compound known as unique for the food or food group (chemical/biological plausibility)?
2. Is there a dose-response relationship at relevant intake levels of the targeted food (quantitative aspect)?
3a. Is the single-meal time-response relationship described adequately (single-dose kinetics)?
3b. Is the biomarker kinetics for repeated intakes of the food/food group adequate (e.g., cumulative aspects)?
4. Has the marker been shown to be robust after intake of complex meals (robustness)?
5. Has the marker been shown to compare well with other markers for the same food/food group (reliability)?
Analytical validation:
6. Is the marker chemically and biologically stable, making measurement reliable (feasibility)?
7. Are analytical variability (CV%), accuracy, sensitivity, and specificity known as adequate (analytical performance)?
8. Has the analysis been successfully reproduced in another laboratory (reproducibility)?
Fig. 1Flow diagram of the study selection
Fig. 2Examples of the most representative metabolites for each herb/spice identified in the reviewed studies. HMDB ID; phytohub code (PHUB); −G, glucuronide; −S, sulfate; aldehyde-menthol glucuronide (M2); menthol sulfate conjugates (M29); in the blood; in urine; in feces; in the intestine; in the liver